The Food and Drug Administration has approved Celltrion's Steqeyma (ustekinumab-stba), a biosimilar to Johnson & Johnson's Stelara (ustekinumab), for subcutaneous injection or intravenous infusion in ...
Imuldosa, a Stelara biosimilar, is approved for autoimmune diseases, marking the fifth ustekinumab biosimilar in the US market. Stelara, a top-grossing biologic, underwent CMS price negotiations with ...
Biocon Biologics has received permission from the Food and Drug Administration for Yesintek (ustekinumab-kfce), which is a biosimilar to Stelara. Yesintek, a monoclonal antibody, is approved for the ...
ORLANDO -- First-dose reactions to IV ustekinumab (Stelara) may be related to IgE recognition of a carbohydrate allergen in patients, who may be able to tolerate subcutaneous ustekinumab instead, ...
PARSIPPANY, N.J. and REYKJAVIK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), and Alvotech (ALVO) today announced that ...
Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results